Resources for Researchers
NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
The specimen repositories are a collaboration between the ACTG and IMPAACT clinical trial networks to make the large body of specimens collected for HIV research available to investigators.
The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibact
Repository of specimens collected as part of the DAIDS VAX004 Clinical Trial.
The MACS collects and stores a variety of biological specimens. Inventory may be housed at the national level or a subset at the local level. The MACS Center for the Coordination and Analysis of MACS (CAMACS) coordinates and facilitates completion of specimen requests.
Researchers involved with the NIAID Clinical Genomics Program study many diseases of the immune system that are rare and not well understood but often shed light on basic immune function and more common immune disorders.
The National Institutes of Health (NIH) AIDS Reagent Program provides critical research reagents and resources to the scientific community. The ARP acquires, develops, and produces state-of-the-art reagents and provides these reagents at no cost to qualified investigators throughout the world.
TrialShare is a transformative approach to data-sharing that enables clinical trial transparency.
The Women's Interagency HIV Study (WIHS) collects and stores a variety of biological specimens. Inventory may be housed at the national level, or a subset at the local level. The WIHS Data Management and Analysis Center (WDMAC) coordinates and facilitates completion of specimen requests.
This resource provides Good Manufacturing Practice (GMP)-quality candidate vaccine viruses for zoonotic influenza, a critical component of global influenza pandemic preparedness.